{"id":41878,"date":"2026-08-25T17:43:15","date_gmt":"2026-08-25T14:43:15","guid":{"rendered":"https:\/\/ral.lv\/2026\/08\/from-the-first-insulin-pumps-to-smart-diabetes-care-minimed-innovations\/"},"modified":"2026-08-26T11:39:15","modified_gmt":"2026-08-26T08:39:15","slug":"from-the-first-insulin-pumps-to-smart-diabetes-care-minimed-innovations","status":"publish","type":"post","link":"https:\/\/ral.lv\/en\/2026\/08\/from-the-first-insulin-pumps-to-smart-diabetes-care-minimed-innovations\/","title":{"rendered":"From the first insulin pumps to smart diabetes care: MiniMed innovations"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t

For diabetics, technological advances mean much more than just smaller devices or faster processors. They can mean fewer injections, better understanding of glucose levels, more freedom in daily life, a better quality of life, and less need to constantly make decisions related to diabetes management. <\/p>

The advancements in insulin delivery and glucose monitoring technology over the past 30 to 40 years have been impressive. Devices that once took up an entire desk or had to be carried around like a backpack have evolved into compact insulin pumps, wearable continuous glucose monitoring sensors, or CGMs, and automated insulin delivery systems that can adjust therapy based on glucose data. <\/p>

MiniMed<\/strong> has been part of this evolution since the early stages of modern insulin pump technology. The company's history, which later continued as Medtronic<\/strong> , shows how long-term research and development can gradually transform an ambitious medical idea into practical, safe and patient-friendly solutions. <\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\"Insulin\t\t\t\t\t\t\t\t\t\t\t
This is an illustrative image of a backpack created with AI \u2013 it may differ from the actual technology<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t

From injections to continuous insulin delivery<\/strong><\/h3>

Many years ago, insulin control and administration for diabetic patients relied on repeated manual injections. The ambitious idea of \u200b\u200bcontinuous insulin delivery promised significant changes and improvements in the quality of life of patients. <\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t

The challenge: glucose measurement and insulin administration as a single process<\/strong><\/h3>

Some of the first attempts were very different from the pumps patients know today. 20. In the 1960s, experimental systems were large and mechanically complex. One of the early closed-loop concepts monitored glucose levels through an intravenous line and used separate pumps for insulin and glucagon. Although this technology was not suitable for everyday use, it demonstrated an important principle: glucose measurement and insulin delivery could work together. This was a major step in the development of subsequent technologies that we take for granted today. <\/p>

Challenge: Mobility<\/strong><\/h3>

In the 1970s, developers began to reduce the size of insulin delivery devices. Dean Kamen's AutoSyringe, developed in 1976, was a major step towards a portable infusion system. The development of precision motors later allowed for the control of very small movements and thus the delivery of the required amount of insulin to the patient with greater precision. <\/p>

MiniMed, founded by Alfred Mann in 1983, evolved during this period of rapid experimentation. The company\u2019s early commercial pumps helped move from repeated injections to programmable, continuous insulin delivery. This shift wasn\u2019t just a matter of convenience. It also posed a whole new engineering challenge: a device that continuously delivered a potent drug had to be reliable and precisely controllable. <\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\"Auty\t\t\t\t\t\t\t\t\t\t\t
This is an illustrative image of AutoSyringe, created with AI \u2013 it may differ from the actual technology <\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t

Initially, this solution raised concerns among both users and doctors about accidental over-injection of insulin due to technical failure. Therefore, the development of insulin pumps required extensive testing studies, very strict safety controls and the accumulation of experience. Over time, the technology became more reliable, safer and more accurate. <\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t

A radically different approach: an implantable insulin pump<\/strong><\/h3>

MiniMed's work was not limited to external pumps. In the late 1970s, Alfred Mann assembled a team of engineers to explore an even more ambitious idea: an insulin pump that could be implanted in the human body. The project was carried out in collaboration with NASA and the Johns Hopkins University Applied Physics Laboratory. The result was the Programmable Implantable Medication Delivery System, or PIMS, which was designed to deliver insulin into the intraperitoneal cavity rather than subcutaneous tissue. <\/p>

This difference was important because this route of administration can better mimic certain aspects of the body's natural insulin action. The technology progressed from an idea to clinical trials. The first such pump was implanted at Johns Hopkins Hospital (USA) in 1986, and further clinical trials continued in the following years. <\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\"Implanted\t\t\t\t\t\t\t\t\t\t\t
This is an illustrative image of an implanted pump, created with AI \u2013 it may differ from the actual technology.<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t

One patient who later became closely involved with the technology was Greg Peterson. He received his first implantable pump in January 1992 as part of a clinical trial. According to Peterson, the early studies focused on safety and system effectiveness. In addition to effectiveness and quality of life improvements, early implantable pump patients, doctors, and scientists faced challenges related to batteries, catheters, communication components, insulin stability, and maintenance. Patients and engineers were effectively pioneers, learning together how to use and improve the new technology. <\/p>

Some patients became very loyal to the system. Peterson used implantable pumps for about 30 years. When support in the United States became limited, he flew dozens of times from California to France to get the necessary maintenance for his device. <\/p>

These individual patient experiences should not be taken as clinical evidence that automatically applies to all patients. However, they do illustrate another important point: diabetes technology is not only about the technical aspects, but also about how the patient feels and how comfortable the system is to use on a daily basis. <\/p>

Watch the video where you can see and learn more about the technologies described above and their development.<\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t

Glucose monitoring is a game changer<\/strong><\/h3>

While insulin delivery technology was evolving, another major change in glucose measurement was occurring at the same time. The early home glucose meters that became available in the 1970s. Back then, they were large devices. Measuring glucose required significantly more time and effort than today, and each measurement only showed a single point in time. This was a major limitation. For example, a glucose reading of 120 mg\/dL did not, by itself, tell us whether glucose levels were rising, falling, or remaining stable. Continuous glucose monitoring changed that. <\/p>

MiniMed<\/strong> introduced one of the early CGM solutions in 1999. Compared to today\u2019s discrete sensors, it was a bulky, body-worn sensor that was connected to a relatively large device that the user had to carry with them. Later generations introduced wireless data transmission, and the devices gradually became smaller and more convenient. Despite its initial limitations, CGM fundamentally changed diabetes management. <\/p>

Instead of individual measurements, patients and doctors could begin to see glucose trends that occurred after meals, during exercise, and at night. This continuous stream of data paved the way for an even more important step: connecting the glucose sensor to an insulin pump. <\/p>

From glucose monitoring to automatic response<\/strong><\/h3>

2001. In 2011, Medtronic acquired MiniMed, integrating the company's insulin pump and CGM technologies into its broader medical device portfolio. In the years that followed, the two technologies were increasingly combined. 2025. In 2011, Medtronic used the pump hardware as a CGM receiver. A year later, MiniMed allowed CGM data to be displayed directly on the insulin pump and alerted the user when glucose levels were too high or too low. At this stage, the patient still had to interpret the information and make their own decisions about what to do. <\/p>

The next step, therefore, wasn't just a better sensor or a better pump. It was the introduction of automation. <\/p>

Algorithm-driven safety feature<\/strong><\/h3>

2013. In 2011, the Medtronic 530G introduced an algorithm-driven safety feature that could suspend insulin delivery in response to low glucose levels under certain conditions. This was a major turning point: the pump no longer simply followed preset commands from the user. Glucose data could automatically influence insulin delivery. From there, automated insulin delivery continued to evolve to today\u2019s hybrid closed-loop systems. <\/p>

Such systems regularly analyze CGM readings and adjust background insulin delivery to help keep glucose levels within a specific target range. The patient still participates in some treatment decisions, particularly regarding meals, hence the term \u201chybrid closed loop.\u201d <\/p>

As a result, several technological elements developed over decades are combined into one system: accurate glucose sensors, reliable insulin pumps, wireless communication, and increasingly complex control algorithms.<\/strong><\/p>

Competence that develops over decades<\/strong><\/h3>

The history of MiniMed's development helps us understand what competence really means in the field of medical technology. Expertise doesn't come from one successful product. It comes from years of solving complex problems. <\/p>